Quality of Mycoplasma Strains: A Key Factor Determining the Reliability of Limit of Detection (LOD) for Nucleic Acid Amplification Assays

18

2026.06

Upgrading HCD Quality Control for Biologics: A Scientific Risk Control Transformation from Total Quantity Limitation to Fragment Analysis

17

2026.06

Research Supports Influenza Vaccine Safety: Analytical Method for Host Cell Residual DNA Fragments in H5N1 Inactivated Whole-Virus Influenza Vaccine

16

2026.06

From ELISA to LC-MSMS Dual-Platform Strategy and Industry Trends for Residual Host Cell Protein (HCP) Detection

10

2026.06

Analysis of Low-Abundance Host Cell Residual Protein Detection in Monoclonal Antibody Drugs by Liquid Chromatography-Tandem Mass Spectrometry

09

2026.06

European Pharmacopoeia 2026 New Regulation: Simultaneous Testing of Cells and Supernatant Mandatory for Mycoplasma Detection, NAT Method Officially Upgraded as One of the Three Core Methods

05

2026.06

Practical Solutions to Three Major Pain Points in Host Cell Protein ELISA Detection Specificity Bias, Dilution Non-Linearity and Abnormal Recovery

03

2026.06